Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Oncol. Apr 24, 2025; 16(4): 104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827

Table 7 Treatment adherence rate of patients with pregabalin during the study period of 8 weeks

Adherence rate	Number of patients	Percentage of total patients (%)
Completed study period	10	100

Citation: Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827
URL: https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i4.104827

Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827 [PMID: 40290681 DOI: 10.5306/wjco.v16.i4.104827]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.